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Abstract: The reduction of oxygen partial pressure in growing tumors triggers numerous survival
strategies driven by the transcription factor complex HIF1 (Hypoxia Inducible Factor-1). Recent
evidence revealed that HIF1 promotes rapid and effective phenotypic changes through the induction of
non-coding RNAs, whose contribution has not yet been fully described. Here we investigated the role
of the hypoxia-induced, long non-coding RNA H19 (lncH19) and its intragenic miRNA (miR-675-5p)
into HIF1-Wnt crosstalk. During hypoxic stimulation, colorectal cancer cell lines up-regulated the
levels of both the lncH19 and its intragenic miR-675-5p. Loss of expression experiments revealed that
miR-675-5p inhibition, in hypoxic cells, hamperedβ-catenin nuclear localization and its transcriptional
activity, while lncH19 silencing did not induce the same effects. Interestingly, our data revealed that
miRNA inhibition in hypoxic cells restored the activity of Glycogen Synthase Kinase 3β (GSK-3β)
reducing the amount of P-Ser9 kinase, thus unveiling a role of the miR-675-5p in controlling GSK-3β
activity. Bioinformatics analyses highlighted the serine/threonine-protein phosphatases PPP2CA,
responsible for GSK-3β activation, among the miR-675-5p targets, thus indicating the molecular
mediator through which miR-675-5p may controlβ-catenin nuclear localization. In conclusion, here we
demonstrated that the inhibition of the hypoxia-induced non-coding RNA miR-675-5p hampered the
nuclear localization of β-catenin by regulating GSK-3β activity, thus proposing the miR-675-5p as a
new therapeutic target for the treatment of colorectal cancer.
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1. Introduction
Colorectal cancer (CRC) is a heterogeneous disease with an environmental, genetic and biochemical
background. It is the third most commonly diagnosed cancer and the fourth in terms of cancer-related
deaths, and it is expected to increase worldwide by 60% with more than 2.2 million new cases and
1.1 million cancer deaths by 2030 [1]. Mutations in Adenomatous Polyposis Coli (APC) gene and/or
its hyper-methylation are events common to ~80% of sporadic colorectal tumors and often represent
the driver event for further occurrence of mutations. APC constitutes, together with Axin, Glycogen
synthase kinase 3β (GSK-3β), and Casein kinase 1 (CK1), the “degradation complex”, a multiprotein
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complex responsible for β-catenin phosphorylation, poly-ubiquitination and subsequent degradation
through proteasome [2]. The binding of canonical Wnt ligand to its receptors inactivates the degradation
complex, allowing for β-catenin nuclear translocation and the induction of its targets in cooperation
with the TCF/LEF transcription factors. In CRC, Wnt signaling dysregulation is associated with
proliferation, invasion, differentiation, and cell resistance both in early stages as well as during cancer
progression [3].
Even if Wnt//β-catenin pathway dysregulation is most often due to APC mutations, it is also
reported that approximately 1% of CRC patients with wild-type APC have activating mutations in the
β-catenin protein [4]. Interestingly, APC and β-catenin mutations are mutually exclusive events and
associate with different types of colorectal tumors [5].
The accumulation of mutations in one or more genes promotes the onset and progression of cancer;
meanwhile, the molecular alterations in the tumor microenvironment endorse its aggressive phenotype.
Within a growing neoplastic mass, the reduction of oxygen partial pressure and the activation of
hypoxic responses are among the drivers for the CRC metastasizing process [6]. The rapid growth
of the primary tumor is not sufficiently supported by a concomitant development of the vascular
system; this determines a reduction of oxygen partial pressure in the tumor microenvironment, and
the stabilization of the transcription factor HIF-1α (Hypoxia Inducible Factor-1α), that, accumulated
in the nucleus, will form a stable complex with the HIF-1β subunit. The binding of HIF1 complex
to genes with functional hypoxia response elements (HREs) induces, in hypoxic cells, the activation
of numerous survival strategies, i.e., the metabolic reprogramming, the maintenance of stemness,
motility, invasion, angiogenesis, immune suppression, resistance to apoptosis and chemoresistance [7].
These phenotypic transformations are ascribable to the large number of HIF1 targets, among which
have been counted more than 70 coding-genes, and to which have been recently added numerous
non-coding RNAs that support HIF1 activity both at epigenetic and post-transcription level [8–11].
Functional HRE elements have been found in the promoter region of the long non-coding RNA H19
(lncH19), and oncogenic roles have been attributed to hypoxia-induced lncH19 [12,13]. Moreover,
it has been demonstrated that in the hypoxic tumor, together with the increase of lncH19, there is a
selective increase of miR-675-5p, one of the two microRNAs (miRNAs) located in the first exon of the
long non-coding [14–16]. In glioblastoma, miR-675-5p is necessary for maintaining hypoxic responses
by controlling the HIF1α mRNA stability [15] and, in CRC, it participates in tumor progression by
regulating HIF1α-induced EMT (epithelial-mesenchymal transition) [14]. Recently, growing evidence
demonstrated that Wnt and HIF pathways synergize in promoting the tumor growth [17–22]. With the
aim to identify molecular mechanisms through which the two pathways could reinforce each other, in
this study, we investigated the role of hypoxia-induced non-coding RNAs (lncH19 and miR-675-5p) on
two different CRC cell lines: the SW620 and the HCT116, that display, respectively, mutation in APC
and β-catenin [5,23,24].
2. Results
2.1. Hypoxia Upregulates the Expression of Both miR-675-5p and lncH19 in CRC Cell Lines with Mutated Wnt
Pathway Components
In order to investigate the role of early-induced non-coding RNA during hypoxic stimulation,
CRC cell lines SW620 and HCT116 underwent hypoxic chamber stimulation for 18 h. Both cell
lines physiologically respond to low O2 partial pressure stimulation by increasing the amount of
nuclear HIF1α transcription factor as indicated by the ELISA assay in Figure 1A,B. Moreover, HIF1α
transcriptional activity was confirmed by the increase in the expression levels of two of its targets,
VEGF and SNAIL1 [25,26], in respect to their levels in normoxic conditions (Figure 1C,D).
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Figure 1. CRC cell lines up-regulated miR-675-5p and lncH19 after 18 hours of hypoxic stimulation. 
ELISA assay for HIF-1α performed with nuclear extracts of SW620 (A) and HCT116 (B) after 18 hours of 
hypoxic stimulation, positive control was furnished by the kit and it is the nuclear extract of HeLa cells 
pretreated with LiCl. Data, expressed as absorbance (ABS) values at 450 nm, are the mean ± SD of three 
independent experiments. Real-time PCR for VEGF, SAIL1, miR-675-5p and lncH19 in SW620 (C,E) and 
HCT116 (D,F) stimulated for 18 hours in the hypoxic chamber. MiR-675-5p data were normalized for 
Figure 1. CRC cell lines up-regulated iR-675-5p and lncH19 after 18 h of hypoxic sti ulation.
ELISA assay for HIF-1α performed with n l xtracts of SW620 (A) and HCT116 (B) after 18 h of
hypoxic stimulation, positive control was furnished by the kit and it is the n l ct of eLa cells
pretreated with LiCl. Dat , expres e rbance (ABS) values at 450 nm, are the mean ± SD of
three independent experiments. Real-time PCR for VEGF, SAIL1, miR-675-5p and lncH19 in SW620
(C,E) and HCT116 (D,F) stimulated for 18 h in the hypoxic chamber. MiR-675-5p data were normalized
for RNU6 (RNA, U6 Small Nuclear 1) while VEGF, SNAIL1, and lncH19 levels were normalized for
β-actin, ∆∆Ct is expressed as fold of increase (FOI) with respect to normoxic conditions. Data are
expressed as the mean ± SD of three independent experiments and p-values are indicated in the graph.
As previously demonstrated for SW620 cells [14] and here confirmed also for HCT116 cells,
hypoxic stimulation induced also an increase in the transcription of two non-coding RNAs: the long
non-coding RNA H19 (lncH19) and its intragenic miRNA miR-675-5p (Figure 1E,F). The correlation
among lncH19 and CRC has been widely investigated [27–30] as well as its crosstalk with Wnt
pathway [31] while not much is known about the role of hypoxia-induced miR-675-5p in colon cancer.
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Bioinformatics analysis performed by the Kaplan-Meier plotter online tool, shown in Figure 2A,
suggested that high levels of miR-675 are associated with a poor prognosis in rectal cancer
(n = 160, p < 0.05). Moreover, the analysis of miR-675 targeted pathways, conducted by the use
of miRWalk2.0 [32], indicate a significative interaction among miR-675 and both Wnt pathway genes
and CRC associated genes (Table S1).
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cancer patients. The plot was drawn by using the online Kaplan–Meier plotter tool. Patients were divided 
into low and high expression groups based on an upper-tertile cut off value of 20. (B) Real-time PCR for 
miR-675-5p in SW620 (on the left) and HCT116 (on the right) transfected with AntimiR-675-5p, siH19 or 
relative scrambled negative control and subjected to 18 hours of hypoxic stimulation. (C) Real-time PCR 
for lncH19 in SW620 (on the left) and HCT116 (on the right) transfected with AntimiR-675-5p, siH19 or 
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Figure 2. MiR-675-5p regulation (A) Kaplan–Meier curve for overall survival in the cohort of 160 rectal
cancer patients. The plot was drawn by using the online Kaplan–Meier plotter tool. Patients were
divided into low and high expression groups based on an upper-tertile cut off value of 20. (B) Real-time
PCR for miR-675-5p in SW620 (on the left) and HCT116 (on the right) transfected with AntimiR-675-5p,
siH19 or relative scrambled negative control and subjected to 18 h of hypoxic stimulation. (C) Real-time
PCR for lncH19 in SW620 (on the left) and HCT116 (on the right) transfected with AntimiR-675-5p,
siH19 or relative scrambled negative control and subjected to 18 h of hypoxic stimulation. MiR-675-5p
data were normalized for RNU6 (RNA, U6 Small Nuclear) while lncH19 levels were normalized for
β-actin, ∆∆Ct is expressed as fold of increase (FOI) with respect to scrambled negative control. Data are
expressed as the mean ± SD of three independent experiments and p-values are indicated in the graph.
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These data prompted us to investigate if the hypoxia-induced non-coding RNAs participate in the
dysregulating β-catenin activity.
2.2. MiR-675-5p Controls Beta Catenin Nuclear Translocation
In order to identify the specific role of miR-675-5p and/or lncH19 in hypoxic cells, CRC cell lines
were transfected with miR-675-5p inhibitor or silenced for lncH19 expression before undergoing the
hypoxic stimulus. The efficiency of the inhibition is shown in Figure 2B,C. Although it is widely
assumed that miR-675-5p is obtained by the processing of lncH19, it is to be noted that in hypoxia,
the silencing of lncH19 did not affect miR-675-5p expression levels, the same occurred for miR-675-p
inhibition against H19 expression levels.
Firstly, we investigated β-catenin protein levels in CRC cell lines inhibited for the expression of
miR-675-5p (antimiR-675-5p) or for lncH19 (siH19) and undergone to hypoxic stimulation. As shown
by the Western blot in Figure 3A,B the non-coding RNAs’ inhibition did not affect the protein amounts
in both cell lines. It has been largely described that hypoxic stimulation promotes β-catenin nuclear
localization also in CRC cells which, already in normoxia, showed β-catenin nuclear activity [33–35].
Interestingly, the immunofluorescence analyses, in Figure 3C, revealed that miR-675-5p inhibition
reduced the hypoxia-induced nuclear accumulation of β-catenin in both cell lines while the lncH19
silencing did not show the same effects. The trend of the nuclear reduction is confirmed by the Western
blots in Figure S1 (SF1).
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Then, we investigated the effects on β-catenin transcriptional activity induced by miR-675-5p 
and/or lncH19 silencing in hypoxic cells. To this aim, we transfected cells with the TOP-Flash 
FOP-Flash vectors that contain consensus TCF/LEF binding element (respectively, wild type or 
mutated) upstream of luciferase expression construct. The graphs in Figure 4A demonstrated that 
the transcriptional activity of β-catenin on TCF/LEF promoter is affected by miR-675-5p inhibition in 
hypoxic cells. As expected, no variation in the luciferase activity was revealed in response to the 
Figure 3. Effects induced on β-catenin by miR-675-5p inhibition or lncH19 silencing. Representative
images and densitometric analyses of the Western blots for β-catenin on total extract proteins from
SW620 (A) and HCT116 (B) transfected with AntimiR-675-5p, siH19 or scrambled negative control and
subjected to 18 h of hypoxic stimulation. Data are expressed as the mean ± SD of three independent
experiments. (C) Immunofluorescence for β-catenin on SW620 (upper panels) and HCT116 (lower
panels) in the differe t culture con itions. Normoxic cells transfected with scrambled negative control,
hypoxic c lls transfected with AntimiR-675-5p, siH19 or relative scrambled negative control. β-catenin
in g een, Hoechs stained nuclei in blue. The blue scale bar is 50 µm (in SW620) while the white one is
20 µm (in HCT116).
Then, we investigated the effects on β-catenin transcriptional activity induced by miR-675-5p
and/or lncH19 silencing in hypoxic cells. To this aim, we transfected cells with the TOP-Flash FOP-Flash
vectors that contain consensus TCF/LEF binding element (respectively, wild type or mutated) upstream
of luciferase expression construct. The graphs in Figure 4A demonstrated that the transcriptional
activity of β-catenin on TCF/LEF promoter is affected by miR-675-5p inhibition in hypoxic cells.
As expected, no variation in the luciferase activity was revealed in response to the different treatments
in cells transfected with the mutated promoter (FOP). Further confirmation was obtained by the
transcriptional analysis for the β-catenin targets c-MYC and Cyclin D1, involved in regulating tumor
growth and cellular proliferation. As shown by the RT-PCR graphs in Figure 4B, miR-675-5p inhibition
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reduced both c-MYC and Cyclin D1 expression in hypoxic CRC cell lines. While c-Myc is known to be
down-regulated also by HIF complex in prolonged hypoxia [36,37], it is noteworthy the inhibitory
effect induced by miR-675-5p on Cyclin D1 expression, which we found up-regulated in hypoxic CRC
cells as shown in Supplementary Figure S2 (SF2).
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 18 
 
different treatments in cells transfected with the mutated promoter (FOP). Further confirmation was 
obtained by the transcriptional analysis for the β-catenin targets c-MYC and Cyclin D1, involved in 
regulating tumor growth and cellular proliferation. As shown by the RT-PCR graphs in Figure 4B, 
miR-675-5p inhibiti n reduced both c-MYC and Cyclin D1 expression in hypoxic CRC cell lines. 
While c-Myc is known to be down-regulated also by HIF complex in prolonged hypoxia [36,37], it is 
noteworthy the inhibitory effect induced by miR-675-5p on Cyclin D1 expression, which we found 
up-regulated in hypoxic CRC cells as shown in Supplementary Figure S2 (SF2). 
 
Figure 4. Effects induced on β-catenin activity by miR-675-5p inhibition or lncH19 silencing in hypoxic 
cells. (A) Dual Glo luciferase assay on SW620 (left graph) and HCT116 (right graph) transfected with 
TOP- Flash or FOP-Flash plasmid in normoxic condition or co-transfected with AntimiR-675-5p, siH19 or 
scrambled negative control, and subjected to 18 hours of hypoxic stimulation. Normoxic cells transfected 
with TOP-Flash or FOP-Flash plasmid and treated with LiCl were used as positive control of the assay. 
Data are expressed as the mean ± SD of three independent experiments. The p-values of the differences 
Figure 4. Effects induced on β-catenin activity by miR-675-5p inhibition or lncH19 silencing in hypoxic
cells. (A) Dual Glo l ciferase assay on SW620 (left graph) and HCT116 (right graph) transfected with
TOP- Flash or FOP-Flash plasmid in normoxic condition or co-transfected with AntimiR-675-5p, siH19
or scrambled negative control, and subjected to 18 h of hypoxic stimulation. Normoxic cells transfected
with TOP-Flash or FOP-Flash plasmid and treated with LiCl were used as positive control of the assay.
Data are expressed as the mean ± SD of three independent experiments. The p-values of the differences
between TOP vectors are indicated in the graph, while the * indicates the p-values of the difference
between TOP and FOP for each condition. * < 0.05, ** < 0.005, *** < 0.0005. (B) Real-time PCR for c-MYC
and Cyclin D1 in SW620 (left panels) and HCT116 (right panels) transfected with AntimiR-675-5p,
siH19 or relative scrambled negative control and subjected to 18 h of hypoxic stimulation. Gene
expression data were normalized for β-actin, ∆∆ct is expressed as fold of increase (FOI) with respect to
the expression in the scrambled negative control transfected cells. Data are expressed as the mean ± SD
of three independent experiments and p-values are indicated in the graph.
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2.3. MiR-675-5p Inhibition in Hypoxic Cells Promotes GSK3β Activation
To identify the molecular mediators by which miR-675-5p may control β-catenin nuclear
translocation, we focused on the Wnt pathway genes that showed miR-675-5p target sequences
on their transcripts, and in particular, on the Ser/Thr kinases GSK3β, the core protein of the “destruction
complex” which phosphorylates β-catenin at Ser33 and Ser37 residues [38].
MiRWalk2.0 [32] analysis (Table S2) identified consensus sequences for miR-675-5p on GSK3β, but
also in the three serine/threonine-protein phosphatases (PPP2CA, PPP2R1A, PPP2R2B) that form the
PP2Ca_R1A_Bd complex. The latter controls GSK3β activation by Ser9 residue de-phosphorylation, as
shown in SIGNOR 2.0 database [39], a database of causative relationships between biological entities
coming from scientific literature (https://signor.uniroma2.it/relation_result.php?id=SIGNOR-C133&
organism=human).
First, we evaluated the effects of miR-675-5p inhibition on GSK3β. By the use of ELISA assay, we
found that the total amount of GSK3β was not affected by hypoxic stimulation, either by miR-675-5p
inhibition or by lncH19 silencing (Figure 5A,B). Intriguingly, evaluating the inactive P-Ser9-GSK3β,
we found that the hypoxic stimulus had an inhibitory effect on the GSK3β activity, but this inhibition
was lost when the cells were transfected with antimiR-675-5p; these results indicated that miR-675-5p
has a role in maintaining GSK3β inactive in hypoxic cells. In Figure 5C,D, the amount of inactive
P-Ser9-GSK3β was normalized for the total amount of GSK3β in the different conditions, and reported
as fold of induction versus the equivalent in hypoxic controls.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 9 of 18 
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transfected with miR-675-5p mimic or scrambled control under normoxic condition, and 
phosphatases’ RNA levels were analyzed by real-time PCR. As shown in Figure 6 (C,D), miR-675-5p 
mimic, in both cell lines, reduced RNA levels for both PPP2CA and PPP2R2B, respectively, and the 
catalytic subunit and the B regulatory subunit of the serine/threonine-protein phosphatase 2A, while 
no effects were had on PPP2R1A mRNA amount; however, we cannot exclude an effect of 
miR-675-5p on the phosphatases’ translation levels. 
Figure 5. MiR-675-5p inhibition favors GSK3β activation in hypoxic cells. Total GSK3β assay in SW620
(A) and HCT116 B) transfected with AntimiR-675-5p, siH19 or relativ negative control and subjected
to 18 h of hypoxic stimulation, or transfected with the scrambled negative control and maintained in
normoxic condition. Data are expressed as absorbance (ABS) values at 450 nm, and are represented
as the mean ± SD of three independent experiments. Total/P-Ser9-GSK3β ELISA assay in SW620
(C) and HCT116 (D) treated as de cribed abov . Data of P-Ser9-GSK3β were normalized for total
GSK3β and expressed as fold of increase (FOI) with respect to the P-Ser9 GSK3β levels in hypoxic cells
transfected with scrambled negative control. Data are expressed as the mean ± SD of three independent
experiments and p-values indicated in the graph.
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Then, we moved to validate the three serine/threonine-protein phosphatases of the PP2Ca_R1A-Bd
as miR-675-5p targets. The transcriptional analysis of the three serine/threonine-protein phosphatases
(PPP2CA, PPP2R1A, PPP2R2B) in Figure 6A,B showed that hypoxic stimulation strongly
down-regulated the mRNA levels of all of them. Then, to investigate if this inhibitory effect might be
due to miR-675-5p hypoxia-induced over-expression, cells were transfected with miR-675-5p mimic
or scrambled control under normoxic condition, and phosphatases’ RNA levels were analyzed by
real-time PCR. As shown in Figure 6C,D, miR-675-5p mimic, in both cell lines, reduced RNA levels for
both PPP2CA and PPP2R2B, respectively, and the catalytic subunit and the B regulatory subunit of
the serine/threonine-protein phosphatase 2A, while no effects were had on PPP2R1A mRNA amount;
however, we cannot exclude an effect of miR-675-5p on the phosphatases’ translation levels.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 10 of 18 
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Figure 6. Effect of miR-675-5p on the phosphatases’ mRNA level. Real-time PCR for PP2CA, PP2R2B
and PP2R1A in SW620 (A) and HCT116 (B) under normoxic condition or subjected to 18 h of hypoxic
stimulation. Gene expression data were normalized for β-actin, ∆∆ct is expressed as f ld of increase
(FOI) with respect to the expression in normo ic c lls. Real-time PCR PP2CA, PP2R2B and PP2R1A
in SW620 (C) and HCT116 (D) transfected with miR-675-5p mimic or scrambled negative control
in normoxic conditions subjected to 18 h of hypoxic stimulation. Gene expression data were
nor alized for β-actin, ∆∆ct is expressed as fold of increase (FOI) with respect to the expression in
scrambled negative control transfected cells. Data are expressed as the mean ± SD of three independent
experiments and p-values are indicated in the graph.
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3. Discussion
In this study, by the use of two CRC cell lines mutated in APC and β-catenin, we demonstrated
that the aberrant activation of β-catenin is further supported by hypoxia-induced non-coding RNA
activity/modulation. In particular, we found that in hypoxic cells, the induction of miR-675-5p endorsed
β-catenin nuclear localization by affecting GSK3β activity, thus identifying in the miR-675-5p, a putative
therapeutic target to inhibit aggressive CRC.
In the last few years, the increasing amount of information acquired about the biology of cancer
cells and the molecular mechanisms that govern the onset and progression of the tumor has allowed
the development of new drugs [40,41]. However, the high mortality rate in subjects with CRC and the
increased risk of metastases, including distant bone metastases with subsequent complications such as
pain and pathological fractures due to bone destruction [42,43], indicate the need of more effective and
targeted therapies, especially for the treatment of metastatic colon cancer.
In CRC, lncH19 is considered among the oncogenic long non-coding RNAs [29]. Its role in
promoting the growth and progression of cancer has been traced back to its ability to control gene
expression by interacting with several proteins, including transcription factors, chromatin regulating
proteins, and RNA binding proteins. Its pro-oncogenic role has also been attributed to the ability to
sponge several microRNAs with a tumor suppressor role for CRC, e.g., let-7 and miR200 family [44,45].
Moreover, the lncH19 is the precursor of miR-675, recently found involved in physiological
processes and cancer development, including CRC [14,46,47].
Intragenic miRNAs are largely co-transcribed, and consequently co-regulated with their host
genes. Furthermore, functional linkages between intragenic miRNAs and their hosts on multiple levels
have been identified [48–50]. However, not much is known about the regulation of miR-675; this is
generally associated with lncH19 expression and often considered, by the literature, to be among the
mechanisms of action of the lncH19 itself. Such considerations could lead to believe lncH19 silencing
as an effective strategy to stop cancer progression; this in order to inhibit both the long non-coding
and the miR-675. Our data demonstrated that this strategy would not be successful, at least in the
treatment of CRC.
Notably, we found that the hypoxia-induced miR-675-5p expression was not abolished by lncH19
silencing, thus releasing, at least in part, the synthesis of the miR-675-5p from the long non-coding that
cages it. Moreover, in our system, miR-675-5p inhibition in hypoxic cells is most effective than lncH19
silencing to inhibit β-catenin nuclear activity; the latter characteristic common to 80% of CRCs [51].
Here, we have highlighted a new role for hypoxia-induced miR-675-5p in controlling the β-catenin
nuclear localization in hypoxic cells, with effects that could go well beyond the investigation carried
out so far. In this study, in fact, we focused our interest on the β-catenin targets identified by the
consensus TCF/LEF binding elements, which are expressed also in normoxic condition, due to the
common Wnt pathway mutations in CRCs.
However, it is known that during hypoxia, nuclearβ-catenin is recruited also on HREs to cooperate
physically with HIF1 in activating some of its targets, promoting cell survival and adaptation to
hypoxia [52,53]. Therefore, further studies may reveal that the failure to recruit β-catenin could broadly
affect the hypoxic response, confirming the key role of miR-675 in supporting hypoxic CRC as already
demonstrated for glioblastoma [15].
In addition, our data revealed that the miR-675-5p acts on the nuclear localization of the β-catenin
without affecting the total amount of the protein. Interestingly, in colon cancer, a role of β-catenin at
the cytoplasmic level has emerged where, interacting with other RNA binding proteins, it participates
in the stabilization of several mRNA [54]. Furthermore, it was demonstrated that the cytoplasmic
accumulation of β-catenin, in response to hypoxia, activates a post-transcriptional de-differentiation
and survival program in breast cancer cells [55]. Further efforts should be directed to identifying all
the β-catenin cytoplasmic targets to evaluate whether they are affected in response to hypoxia or to
miR-675-5p inhibition.
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The use of miR-675-5p as a therapeutic target for the inhibition of β-catenin nuclear localization
would have an effect in CRC cells where the APC-mediated GSK3-β-dependent regulation of β-catenin
is functional. Here, it is to note that even if APC mutation was found in 80%–90% of both inherited and
sporadic colorectal cancers, as reviewed by [56], APC-mutated CRCs usually do not carry homozygous
null mutations but keep at least one allele encoding a truncated APC protein that retains a residual
ability to target β-catenin for degradation. This makes the WNT pathway inhibition a viable strategy
for the treatment of the majority of CRCs. We cannot exclude that miR-675-5p inhibition may also have
a role in normoxic cells but further studies are required to investigate this point since normoxic cells
present a cellular and molecular scenario completely different from that one in hypoxia [57–59].
Furthermore, our data demonstrated that miR-675-5p affects GSK3β activity in hypoxic cells, and
although the study focused on β-catenin, it opens the door to additional investigation considering
that GSK3β has regulatory roles in several cellular processes, being the “molecular hub” that connects
pathways responsible for tumor invasion and chemoresistance [60]. Finally, as a putative mechanism
of action for the miR-675-5p, we identified the inhibition of PP2CA, the catalytic subunit of the PP2A
phosphates [61]. This is considered to be a principal guardian against tumorigenic transformation [61,62]
and, interestingly, the evidence from literature indicated that PP2A inhibition is a common event in
several cancers including CRC [63,64].
4. Materials and Methods
4.1. Cell Culture
SW620 and HCT116 cells obtained from DBA were cultured respectively in RPMI (Euroclone, UK)
and in McCoy’s 5A medium (Life Technologies; Carlsbad, CA, USA), supplemented with 10% fetal
bovine serum, 1% penicillin/streptomycin (50 IU/mL) and 2mM glutamine (Life Technologies). Cells
were maintained in a humidified 5% of CO2 atmosphere at 37 ◦C. For all the experiments, cells were
used at an early passage. For hypoxia experiments, both cell lines were seeded at 50.000 cells/cm2 and
were incubated in a hypoxia chamber containing 1% O2 gas mixture for 18 h.
4.2. Transfections
Cells were transfected by using Lipofectamine 3000 reagent (cat. L3000-015, Life Technologies)
following manufacturer’s standard protocol. SW620 and HCT116 cells were seeded at 50.000 cells/cm2
in a 12-well plate, and transfected with 30 pMoles of mirVana™ miRNA Inhibitor hsa-miR-675-5p
(Assay ID: MH12067), or Silencer™ Select Pre-Designed siRNA for long non-coding H19 (siRNA ID:
n502891); mirVana™ Negative Control or Silencer™ Select Negative Control were respectively used
as negative control (ThermoFisher Scientific). Six hours after transfections, cells were incubated in
a hypoxic chamber for 18 h, after which the medium was collected and the cells were processed for
following experiments. For miRNA targets’ validation, SW620 and HCT116 cells were seeded at 50.000
cells/cm2 in a 12-well plate and transfected for 24 h with 30 pMoles of mirVana hsa-miR-675-5p mimic
(Assay ID MC12067) or mirVana™ Negative Control.
4.3. RNA Extraction and Real-Time PCR
Total RNA was extracted using Trizol Reagent (cat. number 15596020, ThermoFisher Scientific)
according to standard protocol. The concentration of total RNA was detected with a Nanodrop
spectrophotometer and 1 µg was used to synthesize cDNA by using High Capacity cDNA Reverse
transcription Kit (cat. 4368814, Applied Biosystem; Foster City, CA, USA). QRT-PCR was done in
48-well plates using the Step-One Real-Time PCR system (Applied Biosystem). TaqMan probes
were used to evaluate the levels of VEGF (Hs00900055_m1), SNAIL (Hs00195591_m1), and H19
(Hs00399294_g1) using β-actin (Hs00357533) as a housekeeping gene. For microRNAs’ evaluation,
10 ng of RNA were reverse-transcripted by TaqMan MicroRNA Reverse Transcription Kit (cat. number
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4366596, Applied Biosystem), and TaqMan® MicroRNA Assays (assay ID: 002005 and assay ID: 001973)
were used to amplify has-miR-675-5p and U6 snRNA.
QRT-PCR analyses with Fast SYBR™ Green Master Mix (ThermoFisher Scientific) were carried
out to evaluate cyclin D1, c-MYC, PPP2CA, PPP2R1A or PPP2R2B mRNA levels and β-actin was
used as a housekeeping gene. The sequences of the primers are reported in Table 1. The fold changes
in the mRNA expression level or miRNA levels normalized respectively to β-actin or U6 snRNA
housekeeping genes were determined with the ∆∆Ct method [65]. The data were expressed as fold of
induction (FOI) of indicated mRNA or miRNA after inhibitor transfection compared to relative controls.
Table 1. Sequences of qRT-PCR primers.
Gene Primer Forward Primer Reverse
β-actin TCCCTTGCCATCCTAAAGCCACC CTGGGGCCATTCTCCTTAGAGAGAAG





4.4. TOP/FOP Luciferase Assay
TOP/FOP flash assay was used to evaluate β-catenin TCF/LEF promoter activity. TOP/FOP vectors
contain two sets of three copies of the TCF binding site (wild type in TOP and mutated in FOP)
upstream of the Thymidine Kinase (TK) minimal promoter and the firefly luciferase open reading frame.
FOP Flash was used as a control for measuring nonspecific reporter activation. SW620 and HCT116
cells seeded at 50.000 cell/cm2 in a 12-well plate were transfected respectively with 100 ng of TOP or
FOP plasmids and then co-transfected with miRNA inhibitor, siH19 or scrambled negative control as
described above. For all luciferase assays, pRenilla-CMV luciferase vector was used as an internal
transfection control, co-transfected in all conditions at 100 ng/mL. After six hours of transfection, cells
were incubated in a hypoxic chamber for 18 h. Lithium chloride (LiCl), a well-established inducer of
β-catenin nuclear activity, was added in some samples as a positive control. Finally, the luciferase
assay was performed with the Dual-Luciferase Assay System kit (cat. E2920, Promega) and results
were detected by GloMax (GloMax-Multi Detection System; Promega). Relative luciferase activity
was reported as the fold induction after normalization for transfection efficiency. Lipofectamine 3000
reagent was used for all the described transfections.
4.5. GSK-3β and HIF-1α ELISA Assays
Total GSK-3β and phosphorylated GSK-3β were quantified using ELISA GSK-3β (Total/Phospho)
Multispecies InstantOne™ ELISA Kit (cat. 85-86173-11, ThermoFisher Scientific) according to the
standard protocol. Briefly, cells were lysed with specific lysis buffer provided by the kit to obtain
protein extract, 50 µg of proteins were added to the coated 96-well plate and analyzed at 450 nm with
Gen5 Microplate Collection and Analysis Software Data.
To detect and quantify HIF-1α transcriptional factor activity, an ELISA assay was performed with
ELISA-based kit (TransAM Kit, cat. 47096, Vinci-Biochem, Italy) following manufacturer’s protocol.
Briefly, nuclear proteins were extracted by using the Nuclear Extract Kit (Vinci-Biochem) and 8 µg of
the samples were added to the coated plate and analyzed at 450 nm with Gen5 Microplate Collection
and Analysis Software Data (BioTek Instruments, Inc.®). Data were expressed as HIF-1α protein
content in total nuclear extract (absorbance).
4.6. Western Blot
SDS-PAGE and Western blotting were performed according to standard protocols. SW620 and
HCT116 cells were lysed for 1h in lysis buffer containing 15 mM Tris/HCl pH 7.5, 120 mM NaCl, 25 mM
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KCl, 1 mM EDTA, 0.5% Triton X100, and protease inhibitor cocktail. Cell debris were removed by
centrifugation at 17.000 rpm for 20 min at 4 ◦C. For nuclear/cytoplasm, differential extraction was
used with the Nuclear Extract Kit (Vinci-Biochem) following manufacturer’s indications. The protein
concentrations were determined by the Bradford microassay method (Sigma; St. Louis, MO, USA)
using bovine serum albumin (BSA, Sigma) as a standard. A total of 20 µg protein from each sample was
separated using Bolt Bis-Tris gel 4%–12% (ThermoFisher Scientific) and transferred on nitrocellulose
membranes (GE Healthcare; Chicago, IL, USA). The membrane was then blocked in 5% BSA solution
(5% BSA, 20 mM Tris, 140 mM NaCl, 0.1% Tween-20) and incubated overnight with primary antibodies:
anti-β-catenin (1:1000, cat. number sc7963, Santa Cruz Biotechnology; Dallas, TX, USA), anti-histone
H1 (1:1500, cat. number 61201, Active Motif®, Carlsbad, CA), anti-lamin B (ThermoFisher Scientific),
and anti-α-tubulin (1:1000, cat. number sc398103, Santa Cruz Biotechnology). The membrane was
incubated with appropriate secondary fluorescent antibody dylight 488 or dylight 594 (ThermoFisher
Scientific) and signal was detected by Chemidoc Biorad acquisition instrument. The obtained images
were analyzed with the Image Lab software (Bio-Rad; Hercules, CA, USA).
4.7. Immunofluorescence Assay
For immunofluorescence, assay cells were fixed in 4% paraformaldehyde, and stained with
β-catenin primary antibody (1:100, cat. number sc7963, Santa Cruz Biotechnology). The secondary
antibody used was Alexa-Fluor 488 (Life Technologies). Samples were counterstained with Hoechst
3342 (1:1000, Life Technologies) for 10 min at room temperature to detect nuclei, and analyzed by
confocal microscopy (Nikon A1) median nuclear planes
4.8. Kaplan-Meier Curves
The potential effect of miR-675 expression on the overall survival of GC patients was investigated
by using Kaplan–Meier plotter online tool (available at https://kmplot.com/analysis/index.php?p=
service&cancer=pancancer_mirna). A cohort of 160 rectal cancer patients was selected, and patients
were divided into low and high expression groups based on an upper-tertile cut off (cut off value = 20).
The analysis was not restricted to a certain tumor stage, gender or race. Survival threshold was set as
“all”, i.e., no patients were excluded or censored from the generation of the plot, no matter how long
they survived. The Compute median survival box was checked, and so was the Censored at threshold
box, but the last one had no effect on the plot computation, because no specific threshold was selected.
4.9. mirWalk Target Prediction and Pathway Mapping
A target prediction and then a pathway mapping of the putative target genes was performed by
using the mirWalk 2.0 [32] database search engine, specifically, the Predicted Target > MicroRNA-Gene
Target module, available at http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/miRretsys-self.html.
The miRbase identifier hsa-miR-675-5p was used as a query, with all the others parameters set as
default. The reference database for pathway mapping was KEGG.
4.10. Statistical Analysis
The data obtained was derived from the mean of at least three experiments, giving reproducible
results, and are represented as the mean ± standard deviation (SD). For statistical analysis, two-tailed
non-parametric Student’s t-test was performed using GraphPad Software Inc. The statistical significance,
if it is present, is reported as p-value in the figures.
5. Conclusions
The presented data highlighted a new molecular mediator in the crosstalk between HIF1 and
β-catenin. These results, together with our previous studies demonstrating that miR-675-5p expression
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enforces the hypoxia-induced EMT in CRC [14], make the miR-675-5p a new interesting target to inhibit
both CRC growth and progression.
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